Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

32.66 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
3 Things About Vertex Pharmaceuticals That Smart Investors Know
Vertex shares have advanced about 20% so far this year. 
Via The Motley Fool
2 Top Healthcare Stocks Defying the Bear Market
These stocks are rising in the double digits -- and outperforming the S&P 500. 
Via The Motley Fool
Sitting on Cash? These 2 Stocks Are Great Buys
Coca-Cola and Vertex Pharmaceuticals are excellent choices to add to your portfolio for the long term. 
Via The Motley Fool
3 Growth Stocks With 55% to 71% Upside, According to Wall Street
Find out why investment bank analysts are so bullish on these stocks. 
Via The Motley Fool
Vertex Pharmaceuticals Stock: Bear vs. Bull
Vertex has reached a key moment in its story. 
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
These companies are coming into their own. 
Via The Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
CRISPR stock has climbed more than 40% so far this year. 
Via The Motley Fool
2 Growth Stocks That Might Be Too Cheap to Ignore
The sky is the limit for these healthcare companies. 
Via The Motley Fool
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025
In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 
Via InvestorPlace
Cathie Wood Continues To Sell Tesla Shares Amid Q2 Deliveries-Induced Strength: Here's How Much Shares Ark Offloaded Monday
Via Benzinga
Where Will CRISPR Therapeutics Be in 10 Years?
The biotech is part of a revolution in gene-editing therapies. 
Via The Motley Fool
3 Stocks That Every 20-Year-Old Should Buy Today
When you’re just starting out in adult life, you have time on your side. Use it to your advantage with these stocks for young investors. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023
If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead. 
Via InvestorPlace
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Both companies have therapies that should help grow revenue and earnings for years. 
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
You can invest in these companies with $20,000 -- or even a lot less. 
Via The Motley Fool
Why Shares of Nkarta Are Slumping Tuesday
The pharmaceutical stock dropped after announcing so-so clinical trial results. 
Via The Motley Fool
Wall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right.
With two huge catalysts drawing near, its stock could go even higher. 
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
3 Monster Stocks in the Making to Buy Right Now
They're not monsters now -- but just give them some time. 
Via The Motley Fool
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
There's more than one reason to sell a stock while buying another. 
Via The Motley Fool
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
This company has several catalysts for growth coming up, with more on the way. 
Via The Motley Fool
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy
Success could be in the DNA of the Ark Invest founder. 
Via The Motley Fool
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
3 Cathie Wood Investments That Could Deliver Superior Returns
These three stocks fit Wood's profile for big-time growth. 
Via The Motley Fool
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.